NewAmsterdam Pharma (NAMS) Shares Outstanding (2021 - 2026)

NewAmsterdam Pharma has disclosed Shares Outstanding across 6 years of filings, most recently posting $116.6 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $116.6 million, up 3.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.6 million (up 3.99% YoY), and the FY2025 annual result was $114.4 million, up 5.86% from the prior year.
• Shares Outstanding came in at $116.6 million for Q1 2026 at NewAmsterdam Pharma, up from $114.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $116.6 million in Q1 2026 to a low of $81.8 million in Q1 2023.
• The 5-year median for Shares Outstanding is $91.1 million (2024), against an average of $97.2 million.
• Across the five-year window, Shares Outstanding surged 1276.14% in 2022 and declined 0.89% in 2023, its largest moves.
• NewAmsterdam Pharma's Shares Outstanding stood at $83.2 million in 2022, then declined by 0.89% to $82.5 million in 2023, then jumped by 31.04% to $108.1 million in 2024, then climbed by 5.86% to $114.4 million in 2025, then rose by 1.96% to $116.6 million in 2026.
• The last three Shares Outstanding figures came in at $116.6 million (Q1 2026), $114.4 million (Q4 2025), and $113.2 million (Q3 2025), per Business Quant data.